CN1214813C - Vulnerary for treating fracture - Google Patents
Vulnerary for treating fracture Download PDFInfo
- Publication number
- CN1214813C CN1214813C CNB2003101099552A CN200310109955A CN1214813C CN 1214813 C CN1214813 C CN 1214813C CN B2003101099552 A CNB2003101099552 A CN B2003101099552A CN 200310109955 A CN200310109955 A CN 200310109955A CN 1214813 C CN1214813 C CN 1214813C
- Authority
- CN
- China
- Prior art keywords
- fracture
- medicament
- treatment
- medicine
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medicament for treating fracture, which comprises an oral application medicament and an external application medicament, wherein the oral application medicament is prepared from angelica, frankincense, myrrh, malaytea scurfpea fruit, sodium tetraborate decahydrate, radix dipsaci from Sichuan of China, rhubarb, natural copper, ground beeltle, cinnabar, dragon's blood and rhizoma drynariae according to a certain weight proportion; the external application medicament is prepared from brown sugar, spirit, slenderstyle acanthopanax bark and ground beeltle. The medicament can rapidly heal fracture, and the functions are synchronously recovered. The medicament has the advantages of simple technology, less damage, low cost and no need of a secondary operation, is an ideal medicament for treating fracture at present and ensures the fracture to be correctly, effectively, rapidly and economically recovered.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of fracture, specifically is the medicine of a kind of oral drugs of feedstock production and the treatment fracture that liniment uses simultaneously with the natural Chinese medicinal herb.
Background technology:
Though the method and the principle of the traditional Chinese medical science, Chinese and western medicine and western medical treatment fracture are not quite similar, and much in common is arranged.The Chinese traditional treatment reduction of the fracture is fixed the external fixation that adopt based on functional reduction more.The traditional Chinese medical science has the complete reduction long bone of limbs fracture of a cover and the method and the fixing means of part intra-articular fracture, and this forms under the particular historical condition.This method still occupies an important position in a lot of treatment of fractures at present, is promoting aspect union of fracture, the functional rehabilitation many have efficacious prescriptions medicine and experiences are arranged.But because the restriction of scientific and technological condition, the traditional Chinese medical science particularly has limitation at serious intra-articular fracture and the extremity fracture of treatment aspect the fracture of ligament, blood vessel, nerve injury, and the course of treatment is long, unsatisfactory curative effect, and what have has a side effect.
Chinese medicine with union of fracture be divided into early, in, back three periods, in treatment, be the Therapeutic Principle in three periods with blood circulation promoting and blood stasis dispelling, reunion of bone, liver and kidney tonifying respectively.Do not have clear and definite boundary three periods, under the total Therapeutic Principle of determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, the Therapeutic Principle in each period has intersection.Chinese medicine thinks that the agglutination of fracture is a stasis of blood newborn process of dispelling.The fracture in early days based on blood stasis, the treatment on based on blood circulation promoting and blood stasis dispelling; Think the kidney generating marrow and dominating bone simultaneously, effecting a permanent cure the stage of fracture middle and late stage, according to the side's of the condemning medication of kidney governing bones theory.Therefore, the side of reunion of fractured tendons and bones is also many going into the medicine of kidney channel, benefiting kidney-YIN kidney yang, and can alleviate, eliminate patient's condition of illness really from curative effect Chinese medicine.
Summary of the invention:
Technical problem to be solved by this invention provide a kind of short treating period, curative effect height, nontoxic, have no side effect and can improve the medicine of the treatment fracture of immunity.
Medicine of the present invention is made up of oral drugs and liniment, and its amount of drug is that the inventor draws through groping in a large number to sum up, and each amounts of components is for all to have better curative effect in the following weight parts scope.Wherein, oral drugs:
Radix Angelicae Sinensis 5-10 Olibanum 2-8 Myrrha 5-10 Fructus Psoraleae 5-10 Borax 5-10
Radix Dipsaci 5-10 Radix Et Rhizoma Rhei 5-10 Pyritum 5-10 Eupolyphaga Seu Steleophaga 5-10 Cinnabaris 5-10
Sanguis Draxonis 5-10 drynaria baronii 5-10
Be preferably:
Radix Angelicae Sinensis 8.6 Olibanums 5.7 Myrrhas 8.6 Fructus Psoraleae 8.6 Boraxs 8.6 Radix Dipsaci 8.6
Radix Et Rhizoma Rhei 8.6 Pyritums 8.6 Eupolyphaga Seu Steleophagas 8.6 Cinnabaris 8.6 Sanguis Draxonis 8.6 drynaria baroniis 8.6
Liniment:
Brown sugar 100-150g Chinese liquor 100-200ml Cortex Acanthopancis 110-150g Eupolyphaga Seu Steleophaga 5-9.
Be preferably:
7 of brown sugar 125g Chinese liquor 150ml Cortex Acanthopancis 125g Eupolyphaga Seu Steleophagas, the child reduces by half.
Oral drugs of the present invention select Radix Angelicae Sinensis, Olibanum, Myrrha, Fructus Psoraleae, Borax, Radix Dipsaci, Radix Et Rhizoma Rhei, Pyritum, Eupolyphaga Seu Steleophaga, Cinnabaris, Sanguis Draxonis, drynaria baronii to make up, application compress select brown sugar, Chinese liquor, Cortex Acanthopancis, Eupolyphaga Seu Steleophaga to make up, make each efficacy of drugs produce synergism, can make rapid healing of fracture, the synchronous rehabilitation of function; Technology is simple, damages for a short time, and economy does not need second operation, is the optimal medicine of treatment fracture at present, guarantees " recovery " that fracture is correct, effective, quick and economical.Its pharmacology is as follows:
Radix Angelicae Sinensis: enrich blood, promoting the circulation of blood, intestine moistening, regulating menstruation.
Myrrha: ulcer sore pain, trusted subordinate, all pains of muscles and bones, traumatic blood stasis, but external expelling pus and promoting granulation.
Olibanum: all pains of blood stasis trusted subordinate, the arthralgia pain clonic spasm of the muscle, ulcer sore pain, traumatic injury, skin infection festers.
Pyritum: the blood and relieving pain that looses promotes union of fracture, reunion of fractured tendons and bones.
Drynaria baronii: the kidney invigorating analgesia, blood circulation-invigorating tendon-strengthening, invigorating the liver and kidney, reuniting the fractured tendons and bones, promoting blood circulation and stopping pain.
Fructus Psoraleae: can the kidney invigorating warm up spleen, controlling nocturnal emission with astringent drugs reducing urination.
Borax: heat clearing away, expectorant, detoxifcation.Cure mainly laryngopharynx swelling and pain, tooth root rots to swell and ache, aphtha, and the order disease, ulcer is choked every, diseases such as long-pending expectorant.The external detoxifcation is anticorrosion, heat clearing away expectorant for oral administration.
Radix Et Rhizoma Rhei: purging heat and dredging bowels, clots absorbing removing mass.The intestines and stomach excess-heat is stagnant, the blood system excess-heat syndrome, and jaundice, edema, blood stasis gathers.The external application detumescence of relieving inflammation or internal heat, carbuncle sore tumefacting virus, burn due to hot liquid or fire.
Radix Dipsaci: invigorating the liver and kidney, reuniting the fractured tendons and bones, invigorate blood circulation, antiabortive, promoting the circulation of blood detumescence, granulation promoting pain relieving, strong waist knee joint.
Cinnabaris: calm the nerves, calm the frightened, detoxify, calm, antibiotic.
Sanguis Draxonis: hemostasis and pain-relieving, blood activating and promoting tissue regeneration.The dissipating blood stasis tissue regeneration promoting, ground is held high hemostasia and promoting granulation and is cured mainly traumatic injury, and blood stasis is had a pain, sudden attack of pain in the chest and abdomen, incised wound is hemorrhage, and skin infection such as does not hold back at disease.
Eupolyphaga Seu Steleophaga: the blood stasis amenorrhea, caking stomachache, the wound blood stasis is had a pain.
Cortex Acanthopancis: wind-damp dispelling, invigorating the liver and kidney and bone and muscle strengthening can be considered a kind of roborant analgesics that has concurrently.Cure mainly rheumatic arthralgia, waist knee joint weakness, beriberi, edema.
The present invention has following advantage compared to existing technology:
1, the used medicine of the present invention all is a pure natural medical, and is nontoxic lightly seasoned, and no special odor is fit to adult, child administration.
2, curative effect height, short treating period, according to the treatment of 360 routine fracture patients statistics, effective percentage 100%, cure rate 100%, and having no side effect is taken the no vomiting and diarrhoea phenomenon in back, and is harmless to liver, brain, the heart, kidney.No hormone-like effect does not have irritated reaction;
3, treating both the principal and secondary aspects of a disease, and can improve immunity in children.
The instructions of taking of oral medicine:
1, obey 2-4g every day, 110g can fully recover;
2, first week is respectively obeyed 2-4g sooner or later.After one week, every night once, once obey 2-4g;
Be a decotion of Chinese medicine to be taken cold with Chinese liquor when 3, taking medicine.
The using method of application compress:
1, medicine being added 125g brown sugar becomes reconciled with 150ml Chinese liquor;
2, be coated in equably on the chi black cloth, wrap in fracture;
3, promptly medicine is taken off after three days.
3. treating both the principal and secondary aspects of a disease, and can improve immunity in children.
Below further sets forth the beneficial effect of medicine of the present invention by testing example, these are tested the routine pharmacodynamics test of medicine of the present invention and the clinical observation on the therapeutic effect of having comprised and test.
[test example 1] acute toxicity test
To mice carried out iV with in the test of two kinds of route of administration, the result shows: the median lethal dose(LD 50) of iV of the present invention is 3.96g/kg, administration fails to measure median lethal dose(LD 50) in the mice, to record maximum tolerated dose be 3.89g/kg.
[test example 2] medicine of the present invention sees Table 1 to the observation of humoral immunization index
Immunoglobulin in pilots before and after table 1 treatment (g/L x ± S)
Group | IgG | IgA | IgM | |||
Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | |
Treatment group matched group | 7.24±0.83 7.65±0.76 | 9.87±0.76 8.85±1.23 | 1.02±0.06 1.04±0.05 | 1.43±0.13 1.13±0.12 | 0.84±0.24 0.82±0.32 | 1.35±0.51 1.24±0.31 |
Table 1 shows: before (1) treatment: treatment group and matched group IgG, IgA, the equal zero difference of IgM (P>0.05).(2) treatment back: treatment group and matched group IgG, IgA, the equal significant difference of IgM (P<0.05).(3) relatively demonstration of front and back on the same group after the treatment, IgG significantly raise (P<0.05) in the treatment group, IgA is highly significant and raises (P<0.01), and IgM does not have significant change (P>0.05), and IgG, IgA, IgM all change not quite (P>0.05) before and after the matched group conventional therapy.
The clinical observation on the therapeutic effect of [test example 3] Drug therapy Pilon fracture of the present invention
1. physical data
This organizes 24 examples, male 19 examples, women 5 examples, 21~65 years old age, one-sided limbs 22 examples, bilateral 1 example.Traumatogenic reason: Falling Injury 12 examples, traffic accident 10 examples injure 1 example by a crashing object.Complication: 5 examples have associated injury, merge spinal fracture 2 examples, merge offside fracture of the tibial plateau 1 example, merge with dislocation of side hip joint central type and hepatorrhexis 1 example, merge offside calcaneus comminuted fracture 1 example.24 routine limbs open injury 3 examples, closed injury 21 examples.Follow up a case by regular visits to 6~60 months time.
2. classification of fracture
Press R ü edi-Allgower typing standard, the I type refers to the fissure fracture of distal tibial articular surface, no articular surface displacement, and the II type refers to have tangible articular surface fracture displacement, but the fracture pulverizing is not serious.The heavy damage of III type articulations digitorum manus face and the serious comminuted fracture of distal tibial.This group I type 5 examples, II type 7 examples, III type 12 examples.
3. clinical trial method
(1) Therapeutic Method
This group expectant treatment (plaster fixation behind manual reduction, plaster fixation or the calcaneal traction) 7 examples (I type 3 examples, II type 1 example, III type 3 examples), operative treatment 17 examples (I type 2 examples, II type 6 examples, III type 9 examples).Fracture operative reduction in 6~8h after wound.Merge the important organ damage and give shock earlier and handle visceral organ injury, the Pilon fracture is given calcaneal traction earlier.Operation is carried out with reference to AO four steps reconstruction method: 1 fibula resets and fixes; 2 distal tibial articular surfaces reset and fixing; The damaged spongy bone bone grafting of 3 metaphysis bones; 4 distal tibial front sides or medial support steel plate internal fixation.
Application compress are used after three days and promptly medicine are taken off; The instructions of taking of oral medicine: obey 2-4g every day, first week is respectively obeyed 2-4g sooner or later.After one week, every night once, once obey 2-4g, took for 4 weeks continuously.Be a decotion of Chinese medicine to be taken cold with Chinese liquor when taking medicine.
(2) efficacy assessment standard
With reference to Bourne the healing evaluation of Pilon fracture is divided into: excellent, good, differ from 3 grades.Excellent finger is completely recovered, and 75% ankle motion recovers, normal gait.Pain does not hinder one's work when very referring to walking.50% ankle motion recovers, and normal gait, two ankles do not have the inward-outward direction displacement, big bone to retrodisplacement between 2~5mm, no dislocation of talus.Difference refers to suffer from acroesthesia, hinders one's work and walks.The ankle joint motions are less than 50%, and swelling is obvious, and there is the medial and lateral malleolus displacement in visible ankle deformity, move greater than 5mm behind the external malleolus, or the back ankle are shifted greater than 5mm the astragalus displacement.
4. observation of curative effect
Therapeutic outcome sees Table 4
Table 2 is observation of curative effect after controlling
Therapeutic Method | I type 5 is routine good poor | II type 7 is routine good poor | III type 12 is routine good poor | Acceptance rate % |
The conservative treatment operative therapy | 2 1 0 2 0 0 | 1 0 0 5 1 0 | 3 0 0 5 3 1 | 100 94.1 |
Table 2 shows: in the treatment in 5 weeks, treat 24 examples with the present invention, conservative treatment 7 examples as a result, acceptance rate 100%; Operative therapy 17 examples, acceptance rate 83.3%.Total acceptance rate is 95.8%, satisfactory effect.
For further specifying drug effect of the present invention, now provide the effect contrast in the treatment fracture of tablet of the present invention and SHENYANG HONGYAO to see Table 3
Table 3 Chinese herbal medicine tablet of the present invention and SHENYANG HONGYAO be the effect contrast in the treatment fracture
The experiment number | Curative effect | The course of treatment | Remarks | |
The Chinese medicinal tablet of treatment fracture | 38 | Good, acceptance rate reaches more than 95%. | Short, the 4-5 weekly dose is little | |
SHENYANG HONGYAO | 40 | Better, acceptance rate 81%. | Long, the lighter needed about 6 weeks, and heavy person needs about 24 months. |
Table 3 shows: Chinese herbal medicine electuary provided by the invention is than SHENYANG HONGYAO good effect, short treating period in the treatment fracture.
Medicine of the present invention curative effect on other type fracture of treatment is not subjected to the restriction of this test example.Medicine of the present invention is applicable to all kinds fracture patient.
The specific embodiment:
The preparation of embodiment 1 oral drugs tablet
Take by weighing Chinese herbal medicine respectively by the prescription composition and be ground into fine powder with the plant pulverizer respectively, it is standby to cross 80 mesh sieves; Get above-mentioned handled thing and merge, cross 80 mesh sieves, take out 3Kg and Icing Sugar (comprising the syrup amount) 1.5Kg, the dried water 600ml system soft material of mixing of low-substituted hydroxypropyl cellulose 0.1g, dextrin 0.3g then, the wet grain of the 16 mesh sieve systems of crossing, dry granular is crossed 14 mesh sieve granulate.Add magnesium stearate 0.5g, mixing, tabletting.
The preparation of embodiment 2 oral drug capsule agent
Take by weighing quantitative Chinese herbal medicine respectively by the prescription composition and be ground into fine powder with the plant pulverizer respectively, it is standby to cross 80 mesh sieves; Get above-mentioned handled thing and merge, cross 80 mesh sieves, take out 600g and dextrin 350g, sodium carboxymethyl cellulose 50g, magnesium stearate 15g mix homogeneously then, cross 80 mesh sieves,,, irritate in capsule, promptly with 60 mesh sieve granulate with dry granulation mechanism grain.
Above embodiment is only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (2)
1, a kind of medicine for the treatment of fracture, it is characterized in that: it is made up of oral drugs and liniment, and wherein, oral drugs are made by following materials of weight proportions medicine:
Radix Angelicae Sinensis 5-10 Olibanum 2-8 Myrrha 5-10 Fructus Psoraleae 5-10 Borax 5-10
Radix Dipsaci 5-10 Radix Et Rhizoma Rhei 5-10 Pyritum 5-10 Eupolyphaga Seu Steleophaga 5-10 Cinnabaris 5-10
Sanguis Draxonis 5-10 drynaria baronii 5-10
Liniment is made by following materials of weight proportions medicine:
Brown sugar 100-150g Chinese liquor 100-200ml Cortex Acanthopancis 110-150g Eupolyphaga Seu Steleophaga 5-9.
2, a kind of medicine for the treatment of fracture according to claim 1, wherein the weight proportion of each crude drug of oral drugs is:
Radix Angelicae Sinensis 8.6 Olibanums 5.7 Myrrhas 8.6 Fructus Psoraleae 8.6 Boraxs 8.6 Radix Dipsaci 8.6
Radix Et Rhizoma Rhei 8.6 Pyritums 8.6 Eupolyphaga Seu Steleophagas 8.6 Cinnabaris 8.6 Sanguis Draxonis 8.6 drynaria baroniis 8.6
The weight proportion of each crude drug of liniment is:
7 of brown sugar 125g Chinese liquor 150ml Cortex Acanthopancis 125g Eupolyphaga Seu Steleophagas.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101099552A CN1214813C (en) | 2003-10-31 | 2003-10-31 | Vulnerary for treating fracture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101099552A CN1214813C (en) | 2003-10-31 | 2003-10-31 | Vulnerary for treating fracture |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539484A CN1539484A (en) | 2004-10-27 |
CN1214813C true CN1214813C (en) | 2005-08-17 |
Family
ID=34335449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101099552A Expired - Fee Related CN1214813C (en) | 2003-10-31 | 2003-10-31 | Vulnerary for treating fracture |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1214813C (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108339039B (en) * | 2018-05-28 | 2021-04-02 | 郑方 | Chinese medicine for treating bone injury |
CN108685997A (en) * | 2018-07-16 | 2018-10-23 | 谢朝阳 | A kind of Chinese medicine preparation and preparation method thereof for damaging fracture |
CN111053831A (en) * | 2019-12-03 | 2020-04-24 | 贾淑荣 | A Chinese medicinal composition for treating fracture, and its preparation method |
CN111297997A (en) * | 2020-01-16 | 2020-06-19 | 钱茂发 | Oral Chinese medicinal composition for treating bone diseases and preparation method thereof |
-
2003
- 2003-10-31 CN CNB2003101099552A patent/CN1214813C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1539484A (en) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101797327B (en) | Chinese medicinal preparation for treating pain caused by orthopedic diseases | |
CN101062194A (en) | Medicine for treating bone disease and fracture and the preparing method thereof | |
CN100417401C (en) | Medicine for blood stanching, stasis transforming and bone joining | |
CN103263591A (en) | External-use medicine for treating neck/lumbar disc herniation and osteoarthropathy | |
CN101637549B (en) | Medicine for treating fracture | |
CN101703662B (en) | Oral Chinese medicament for treating hyperosteogeny | |
CN101185672B (en) | Orally-administered traditional Chinese medicine decoction for treating lumbar hyperosteogeny | |
CN1927256A (en) | Upper, middle and lower part soup, and method for making same | |
CN102342983B (en) | Chinese medicinal composition for treating pain in the legs and numbness of the extremities and preparation method of preparation thereof | |
CN1861155A (en) | Method for preparing traditional Chinese medicine for treating rheumatism and rheumatoid disease, and said medicine thereby | |
CN1214813C (en) | Vulnerary for treating fracture | |
CN101417003A (en) | Traditional Chinese medicine composition for treating vertebras disease | |
CN103463261B (en) | Traditional Chinese medicine preparation for treating lumbar intervertebral disc herniation | |
CN103285203B (en) | Traditional Chinese medicine composition for preventing and treating bone fracture and preparation method thereof | |
CN101095730A (en) | Medicine for treating rheumatism atrophic arthritis | |
CN1927371A (en) | Blood flow promoting pellet and preparing process thereof | |
CN1850227A (en) | Medicine for treating bone fracture | |
CN1332677C (en) | medication for treating bone injuries | |
CN1076617C (en) | Medicine specially for treating caput femoris necrosis, and method for preparing same | |
CN1256127C (en) | Chinese patent medicine for injury of muscle and joint and its preparation | |
CN109010549A (en) | Synthetism expelling wind and activating blood flow pain relieving ointment and preparation method thereof | |
CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
CN101954043A (en) | Medicament for treating hyperosteogeny and preparation method thereof | |
CN103157011B (en) | Traditional Chinese medicine composite for promoting fracture healing | |
CN1066626C (en) | Traumatic paraplegia pills or capsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |